[1]. 中国高血压防治指南修订委员会. 中国高血压防治指南(2024年修订版)[J]. 中华高血压杂志(中英文),2024,32(7):603-700.
[2].《中国高血压防治指南》修订委员会. 中国高血压防治指南2018年修订版[J]. 心脑血管病防治,2019,19(1):1-44.
[3]. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Societ. Journal of Hypertension.June 21, 2023.
[4]. 陈歆,李燕,刘靖,等．高血压患者高质量血压管理中国专家建议[J/OL]．中华高血压杂志. https://link.cnki.net/urlid/11.5540.R.20231212.1333.002
[5]. Yang WY,Melgarejo JD,ThijsL,et al.Association of office and ambulatory blood pressure with mortality and cardiovascular outcomes[J].JAMA,2019,322(5):409-420.
[6]. Parati G, Bilo G, Kollias A, et al. Blood pressure variability: methodological aspects, clinical relevance and practical indications for management - a European Society of Hypertension position paper ∗. J Hypertens. 2023;41(4):527-544.
[7]. Parati G, Torlasco C, Pengo M, Bilo G, Ochoa JE. Blood pressure variability: its relevance for cardiovascular homeostasis and cardiovascular diseases. Hypertens Res. 2020;43(7):609-620.
[8]. Lin Z, Xiao Z, Chen W, et al. Association of long-term time in target range for systolic blood pressure with cardiovascular risk in the elderly: a Chinese veteran cohort study. Eur J Prev Cardiol. 2023;30(10):969-977.
[9]. Fatani N, Dixon DL, Van Tassell BW,et al. Systolic Blood Pressure Time in Target Range and Cardiovascular Outcomes in Patients With Hypertension. J Am Coll Cardiol. 2021;77(10):1290-1299.
[10]. Chen K, Li C, Cornelius V, et al. Prognostic Value of Time in Blood Pressure Target Range Among Patients With Heart Failure. JACC Heart Fail. 2022;10(6):369-379.
[11]. Desai AS, et al. Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. N Engl J Med. 2023 Jul 20;389(3):228-238.
[12]. Dunn,M.E, et al. Agonist antibody to guanylate cyclase receptor NPR1 regulates vascular tone. Nature 633, 654-661 (2024).
